Literature DB >> 8857301

Chronobiotics--drugs that shift rhythms.

D Dawson1, S M Armstrong.   

Abstract

A chronobiotic is defined and levels of action within the mammalian circadian pacemaker system, such as the retina, retinohypothalamic tract, geniculohypothalamic tract, suprachiasmatic nuclei, output and feedback systems are identified. Classes of drug that include the indoleamines, cholinergic agents, peptides, and benzodiazepines, which might act as chronobiotics within these levels, are evaluated. Particular emphasis is placed on the indole, melatonin (MLT). The clinical circumstances for use of chronobiotics in sleep disturbances of the circadian kind, such as jet lag, shift work, delayed sleep-phase syndrome, advanced sleep-phase syndrome, irregular and non-24-hr sleep-wake cycles, are described under reorganized headings of disorders of entrainment, partial entrainment, and desynchronization. Specific attention is given to the blind and the aged. Both human and animal studies suggest that MLT has powerful chronobiotic properties. MLT shows considerable promise as a prophylactic and therapeutic alternative or supplement to the use of natural and artificial bright light for resetting the circadian pacemaker. Throughout this discussion, the hypnotic and hypothermic versus the chronobiotic actions of MLT are raised. Finally, problems in the design of delivery systems for MLT are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857301     DOI: 10.1016/0163-7258(95)02020-9

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  21 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 3.  Melatonin and jet lag.

Authors:  J Waterhouse; T Reilly; G Atkinson
Journal:  Br J Sports Med       Date:  1998-06       Impact factor: 13.800

Review 4.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

5.  Quantitative calculation of human melatonin suppression induced by inappropriate light at night.

Authors:  Yang Meng; Zhenni He; Jian Yin; Yu Zhang; Tianhao Zhang
Journal:  Med Biol Eng Comput       Date:  2011-06-30       Impact factor: 2.602

6.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

7.  Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials.

Authors:  Wei Zhang; Xue-Yan Chen; Su-Wen Su; Qing-Zhong Jia; Tao Ding; Zhong-Ning Zhu; Tong Zhang
Journal:  Neurol Sci       Date:  2015-08-09       Impact factor: 3.307

Review 8.  The relevance of melatonin to sports medicine and science.

Authors:  Greg Atkinson; Barry Drust; Thomas Reilly; Jim Waterhouse
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

9.  Melatonin supplementation in patients with complete tetraplegia and poor sleep.

Authors:  Jo Spong; Gerard A Kennedy; Douglas J Brown; Stuart M Armstrong; David J Berlowitz
Journal:  Sleep Disord       Date:  2013-03-12

10.  Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications.

Authors:  Seithikurippu R Pandi-Perumal; D Warren Spence; Joris C Verster; Venkatramanujam Srinivasan; Gregory M Brown; Daniel P Cardinali; Rüdiger Hardeland
Journal:  J Cent Nerv Syst Dis       Date:  2011-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.